Ventyx Biosciences (VTYX)
(Real Time Quote from BATS)
$2.18 USD
+0.01 (0.46%)
Updated Sep 9, 2024 03:08 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Income Statements
Fiscal Year end for Ventyx Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 208 | 113 | 67 | 7 | 0 |
Income After Depreciation & Amortization | -208 | -113 | -67 | -7 | 0 |
Non-Operating Income | 15 | 5 | -17 | -21 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -193 | -108 | -84 | -28 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -193 | -108 | -84 | -28 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -193 | -108 | -84 | -28 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -207 | -113 | -67 | -7 | 0 |
Depreciation & Amortization (Cash Flow) | 1 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -208 | -113 | -67 | -7 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 58.54 | 52.47 | 12.83 | NA | NA |
Diluted EPS Before Non-Recurring Items | -3.30 | -2.07 | -6.65 | NA | NA |
Diluted Net EPS (GAAP) | -3.30 | -2.07 | -6.65 | NA | NA |
Fiscal Year end for Ventyx Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 35.72 | 41.77 | 50.35 | 57.95 | 57.15 |
Income After SG&A, R&D, and Dept/Amort Expenses | -35.72 | -41.77 | -50.35 | -57.95 | -57.15 |
Non-Operating Income | 3.76 | 3.20 | 3.59 | 3.92 | 3.89 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -31.95 | -38.57 | -46.75 | -54.03 | -53.25 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -31.95 | -38.57 | -46.75 | -54.03 | -53.25 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -31.95 | -38.57 | -46.75 | -54.03 | -53.25 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 70.56 | 61.83 | 59.08 | 58.88 | 58.56 |
Diluted EPS Before Non-Recurring Items | -0.45 | -0.62 | -0.79 | -0.92 | -0.91 |
Diluted Net EPS (GAAP) | -0.45 | -0.62 | -0.79 | -0.92 | -0.91 |